All Stories

  1. Dupilumab efficacy and safety in patients with asthma and blood eosinophils ≥500 cells·µL−1

    Article • European Respiratory Journal, April 2022, European Respiratory Society (ERS)

    Professor Klaus F. Rabe

  2. Benefits of triple therapy in moderate, severe, and very severe COPD: subgroup analysis of the ETHOS trial

    Article • September 2021, European Respiratory Society (ERS)

    Professor Klaus F. Rabe

  3. Effect of dupilumab on severe exacerbations and lung function in patients with baseline blood eosinophils =500 cells/µL

    Article • September 2020, European Respiratory Society (ERS)

    Professor Klaus F. Rabe

  4. Late Breaking Abstract - COPD exacerbation benefits relative to pneumonia risk with budesonide/glycopyrronium/formoterol metered dose inhaler: analyses from ETHOS

    Article • September 2020, European Respiratory Society (ERS)

    Professor Klaus F. Rabe

  5. Exacerbation benefit by blood eosinophil counts with budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels in the ETHOS trial: a subgroup analysis

    Article • September 2020, European Respiratory Society (ERS)

    Professor Klaus F. Rabe

  6. Efficacy and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD: A Subgroup Analysis of the KRONOS Study

    Article • International Journal of Chronic Obstructive Pulmonary Disease, December 2019, Taylor & Francis

    Professor Klaus F. Rabe

  7. Long-Term Safety and Efficacy of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD

    Article • International Journal of Chronic Obstructive Pulmonary Disease, December 2019, Taylor & Francis

    Professor Klaus F. Rabe, M.D., Ph.D. Yoshikazu Inoue

  8. Analysis of exacerbation rates by time interval post-randomization in the KRONOS Phase III study of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler (BGF MDI)

    Article • September 2019, European Respiratory Society (ERS)

    Professor Klaus F. Rabe

  9. Regional analysis of COPD exacerbation rates in the DYNAGITO trial

    Article • September 2019, European Respiratory Society (ERS)

    Professor Klaus F. Rabe

  10. Rating sputum cell quality in clinical trials for asthma and COPD treatment

    Article • International Journal of Chronic Obstructive Pulmonary Disease, January 2019, Dove Medical Press

    Professor Klaus F. Rabe

  11. Cardiovascular disease and COPD: dangerous liaisons?

    Article • European Respiratory Review, September 2018, European Respiratory Society (ERS)

    Professor Klaus F. Rabe

  12. Influence of body mass on predicted values of static hyperinflation in COPD

    Article • International Journal of Chronic Obstructive Pulmonary Disease, August 2018, Dove Medical Press

    Professor Klaus F. Rabe, Claus Vogelmeier

  13. Identification of novel target genes in human lung tissue involved in chronic obstructive pulmonary disease

    Article • International Journal of Chronic Obstructive Pulmonary Disease, July 2018, Dove Medical Press

    Professor Torsten Goldmann, Professor Klaus F. Rabe

  14. Use of a 4-week up-titration regimen of roflumilast in patients with severe COPD

    Article • International Journal of Chronic Obstructive Pulmonary Disease, March 2018, Dove Medical Press

    Professor Klaus F. Rabe, Peter Calverley

  15. GFF MDI for the improvement of lung function in COPD – A look at the PINNACLE-1 and PINNACLE-2 data and beyond

    Article • Expert Review of Clinical Pharmacology, May 2017, Taylor & Francis

    Professor Klaus F. Rabe

  16. Plasminogen activator inhibitor-1 is elevated in patients with COPD independent of metabolic and cardiovascular function

    Article • International Journal of Chronic Obstructive Pulmonary Disease, March 2017, Dove Medical Press

    Professor Klaus F. Rabe, Dr. Benjamin Waschki

  17. copd

    Article • American Review of Respiratory Disease, August 2016, American Thoracic Society

    Professor Klaus F. Rabe

  18. Roflumilast: a review of its use in the treatment of COPD

    Article • International Journal of Chronic Obstructive Pulmonary Disease, January 2016, Dove Medical Press

    Professor Klaus F. Rabe, Peter Calverley

  19. Nebulised budesonide using a novel device in patients with oral steroid-dependent asthma

    Article • European Respiratory Journal, December 2014, European Respiratory Society (ERS)

    Professor Klaus F. Rabe